TUDCA
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.
TUDCA is a low-tax liver and bile-acid support compound: most useful as oral AAS/SARM cycle support, reasonable as a liver-enzyme and bile-flow tool, and more speculative for longevity or insulin-sensitivity goals unless higher clinical-style dosing is used.
Well-tolerated at standard doses; GI adaptation is expected pharmacology, not a warning sign, unless diarrhea is persistent or the user already has IBS-D.
TUDCA is a low-tax liver and bile-acid support compound: most useful as oral AAS/SARM cycle support, reasonable as a liver-enzyme and bile-flow tool, and more speculative for longevity or insulin-sensitivity goals unless higher clinical-style dosing is used.
Main watch item is GI adaptation: loose stool, increased bowel movement frequency, and first-week nausea from the choleretic mechanism, usually settling within 1–2 weeks. IBS-D users are the main poor-fit group. It is not hormonal, suppressive, androgenic, or cardiostimulatory at ordinary supplement doses.
The payoff is specificity: oral 17-alpha-alkylated compounds create cholestatic bile-acid stress, while TUDCA directly supports bile flow, BSEP/NTCP trafficking, and toxic bile-acid anti-apoptotic signaling. NAC and milk thistle are not substitutes; NAC covers glutathione/oxidative demand, while TUDCA covers the bile-acid lane.
Strongest confidence is for liver-support logic during hepatotoxic oral cycles: the article contains specific bloodwork anecdotes with 30–40% ALT/AST improvement on a TUDCA+NAC support stack, plus RCT evidence in PBC and cirrhosis populations. Metabolic benefits are plausible but dose-sensitive; the clearest insulin-sensitivity signal uses 1750mg/day, not the common 250–500mg/day supplement dose.
Do not dose it at the same time as oral AAS/SARMs or bile-acid sequestrants; separate oral performance drugs by 3–4 hours so the bile-acid mechanism does not interfere with absorption.
Intro
Tauroursodeoxycholic acid (TUDCA) is the taurine-conjugated form of ursodeoxycholic acid (UDCA), a secondary bile acid naturally produced by intestinal bacteria.
Found in trace amounts in human bile and historically concentrated in bear bile — the original source in traditional Chinese medicine — TUDCA is now synthesized pharmaceutically from UDCA + taurine conjugation. UDCA is FDA-approved for primary biliary cholangitis (PBC); TUDCA is not FDA-approved as a drug in the US but is available over-the-counter as a supplement and approved pharmaceutically in Italy and China.
TUDCA's primary community application is hepatoprotection during methylated oral steroid cycles. It is classified as a 'chemical chaperone' in the pharmacology literature due to its ability to reduce endoplasmic reticulum (ER) stress and stabilize the unfolded protein response (UPR) — mechanisms that extend its clinical relevance well beyond the liver to diabetes (beta-cell preservation), neurodegenerative disease (ALS Phase II trials), and metabolic health (insulin sensitivity at 1750mg/day).
The compound operates via two parallel protective mechanisms: bile acid homeostasis (stimulating bile flow, preventing toxic bile acid-induced apoptosis via the cAMP/PKA/CD95/JNK pathway) and chemical chaperoning (improving protein folding capacity via ATF6 activation, suppressing the PERK-eIF2α-CHOP apoptotic arm). These mechanisms are distinct and synergistic.
Clinical evidence: One multicenter RCT in PBC (n=199, TUDCA non-inferior to UDCA with better tolerability); one RCT in liver cirrhosis (n=18, 750mg/day); NCT02218619 T1D beta-cell preservation Phase II; Kars et al. insulin sensitivity at 1750mg/day; UDCA meta-analysis (15 RCTs) supporting bile acid therapy broadly. The critical gap: no published RCT in healthy athletes on oral steroids specifically — community use extrapolates from disease-population data, which is mechanistically reasonable but unvalidated in the specific athletic context.
Observed Effects
Liver enzymes: 30–40% reduction in ALT and AST documented in real-world oral AAS user bloodwork with TUDCA + NAC + injectable glutathione stack.
Multicenter RCT (PBC, n=199): TUDCA 750mg/day non-inferior to UDCA for ALP reduction and liver function normalization over 24 weeks. Liver cirrhosis RCT (n=18): significant ALT, AST, bilirubin reduction at 750mg/day vs placebo. UDCA meta-analysis (15 RCTs): significant ALT, AST, GGT, and ALP reductions across PBC, cirrhosis, NAFLD, and drug-induced liver injury. Bilirubin: acute hepatotoxicity case (trenbolone, bilirubin 11× upper limit at hospitalization) resolved to baseline within 1 month on UDCA/TUDCA 600mg/day.
Metabolic: Kars et al. — TUDCA 1750mg/day improved systemic and hepatic insulin sensitivity in obese adults via ER stress reduction in liver and skeletal muscle. NCT02218619 Phase II: TUDCA 1750mg/day being tested for beta-cell preservation in T1D. 2023 Cell Metabolism data: UDCA/TUDCA restores statin-impaired GLP-1 function via the bile acid-microbiota axis, improving blood glucose and A1C. UDCA meta-analysis (2025): reduced total cholesterol, LDL, and triglycerides.
Gut and bile health: improves bile flow and viscosity — reduces oral steroid-induced nausea, appetite suppression, and GI discomfort driven by bile viscosity disruption. Stabilizes gut microbiome by normalizing bile acid composition. Improves bowel regularity and digestive comfort consistent with the choleretic mechanism.
Neuroprotection: TUDCA neuroprotective in animal models of Alzheimer's, Parkinson's, Huntington's, ALS, and cerebral ischemia (Khalaf et al. 2022). ALS Phase II clinical trials: TUDCA safe and potentially disease-modifying — the first neurodegenerative disease treated with hydrophilic bile acids.
Cellular: Vandewynckel et al. 2015 (HCC mouse model) — preventive TUDCA reduced carcinogen-induced liver enzyme elevation and dampened ER stress-driven apoptotic signaling associated with tumor initiation.
Field Reports
AAS cycle users: AST dropped from 70 to 48 units/L (~30% reduction), ALT from 65 to 39 units/L (~40% reduction) on TUDCA + NAC + injectable glutathione + carnitine support stack during a TRT+ cycle at reduced dose.
Values still above reference range but trending toward normalization with expected full normalization at 25–30 units/L with continued support. This is one of the most specific and well-documented first-person bloodwork examples for the TUDCA+NAC stack in an actual AAS context.
Acute hepatotoxicity rescue: 23-year-old hospitalized after running 1000mg trenbolone/week for 8 weeks. Bilirubin 11× upper limit (13.44 mg/dL), ALT 7.5× ULN (425 units/L), AST 4.5× ULN (159 units/L) at admission. Prescribed UDCA/TUDCA 600mg/day post-hospitalization. Within 1 week liver chemistry improved; within 1 month values returned to baseline — a clinically significant recovery from severe hepatotoxicity. This is the most dramatic real-world TUDCA rescue case in the available data.
PBC patient communities: multiple reports of improved lab values and tolerability on TUDCA vs UDCA, with some patients switching after failing to tolerate UDCA's GI side effects. Corroborates the Hong 2016 RCT tolerability finding in the real-world setting.
GI side effects experience: across chronic-illness and supplement communities, the most common report is loose stool adapting within 1–2 weeks. A consistent minority (~10–15%) cannot adapt above 250mg/day. Before-meal timing (vs with-food timing) reported by some chronic illness users to improve GI comfort and efficacy.
Metabolic anecdotes: men's-health TRT user reports liver/kidney enzyme and iron reduction with TUDCA, with anecdotal T3 increase consistent with the bile acid-GLP-1-thyroid axis. Statin user reports improved fasting glucose and A1C after adding TUDCA, consistent with the 2023 Cell Metabolism statin-GLP-1 paper.
Community Consensus
TUDCA is the community standard hepatoprotectant for methylated oral anabolic steroid cycles — considered non-negotiable alongside NAC for any 17-alpha alkylated compound.
The shift away from milk thistle toward TUDCA represents a mechanism-driven evolution: oral AAS create cholestatic stress (impaired bile flow, toxic bile acid accumulation, BSEP dysfunction) that TUDCA directly addresses, while milk thistle's antioxidant mechanism does not target this specific pathology.
The TUDCA-vs-NAC complementarity is frequently debated in community discussions, but the experienced consensus is clear: they work differently and both are needed on harsh orals. GGT is the tiebreaker biomarker — elevated GGT signals NAC demand; elevated ALT/AST with normal GGT signals TUDCA demand. Many users wait until bloodwork shows elevation rather than starting preventively on day 1, which the protocol-aware community identifies as a mistake — TUDCA's preventive mechanism requires it to be present before cholestatic stress accumulates.
Beyond the AAS context, TUDCA is increasingly adopted by longevity and biohacker communities for general hepatic and metabolic health maintenance at 250mg/day. The ER-stress mechanism (protein folding, cellular homeostasis) and insulin sensitivity data at 1750mg/day (Kars trial) drive this expansion. The community standard dose of 500mg/day is likely conservative relative to what the clinical literature supports for systemic metabolic benefit — but cost and GI tolerance limit escalation.
Honest limitation: all clinical trials are in disease populations, not healthy athletes. The extrapolation is mechanistically sound but unvalidated. This matters less for on-cycle hepatoprotection (mechanism matches) and more for the broader longevity/metabolic claims.
Risks & Monitoring
Loose stool and increased bowel movement frequency — the most common side effect, particularly at 500–1000mg/day.
This is a direct pharmacological consequence of the choleretic mechanism: increased bile output stimulates gut motility. It is not a harm signal — it reflects the compound working. Most users adapt within 1–2 weeks. A minority (~10–15% based on informal community reports) cannot tolerate above 250mg/day due to persistent loose stool; these users are advised to stay at 250mg twice daily.
Nausea and mild GI discomfort in the first week. Dose-dependent: 250mg/day generally well-tolerated; 500mg/day causes GI adaptation in some users; 750–1000mg/day causes more pronounced effects requiring gradual titration.
IBS note: IBS-D (diarrhea-predominant) users may experience worsening — start at 125–250mg/day and assess carefully. IBS-C (constipation-predominant) users often find the prokinetic effect beneficial.
Not observed at supplement doses: hepatotoxicity (TUDCA is hepatoprotective), hormonal suppression (no androgen/estrogen receptor activity), cardiovascular effects, nephrotoxicity.
For Women
Monitoring Panels
REQUIRED is a real safety gate. RECOMMENDED is the prudent default. OPTIONAL covers symptoms, risk factors, or tighter tracking.
Establish pre-cycle liver enzyme baseline before starting any oral AAS. ALT and AST: hepatocellular damage markers. Bilirubin: cholestasis indicator. ALP: biliary obstruction. Albumin: synthetic function. Doubling of ALT/AST from baseline mid-cycle warrants discontinuation.
GGT specifically flags oxidative pathway demand and glutathione depletion — distinguishes TUDCA-responsive (cholestatic stress) from NAC-responsive (oxidative stress/glutathione demand) situations. Elevated GGT with normal ALT/AST means add NAC/glutathione, not more TUDCA. GGT remains elevated longer than ALT/AST after hepatic stress.
At 4–6 weeks into an oral steroid cycle, assess whether the hepatoprotective stack is controlling enzyme elevation. Doubling above baseline warrants cycle discontinuation. Bilirubin above 3× normal warrants discontinuation and clinical evaluation.
Oral AAS causes significant lipid dysregulation (HDL suppression, LDL elevation). TUDCA may have modest lipid-lowering effect via cholesterol-to-bile conversion. Baseline and mid-cycle lipid panel guides overall cycle risk assessment and TUDCA dose consideration.
Verify liver enzyme normalization after cycle completion. Expected timeline with TUDCA + NAC support: normalization within 4–8 weeks of stopping the oral compound. Persistent elevation above 2× normal at 8 weeks post-cycle warrants clinical evaluation.
Avoid With
Do not combine TUDCA with the following. Sorted highest-severity first.
Why:Bile acid sequestration — TUDCA taken simultaneously with lipophilic oral drugs (AAS, SARMs) may alter their first-pass hepatic handling or enterohepatic recycling, potentially reducing bioavailability of the co-administered drug.
What to do:Not a hard contraindication. Practical split: TUDCA with morning meal, oral compound with later meal (afternoon or evening).
Why:Bile acid sequestrants bind bile acids in the gut and prevent their absorption and enterohepatic recycling — directly competing with and negating TUDCA's mechanism of action. The sequestrant would also bind TUDCA itself, preventing its absorption.
What to do:Rare combination in the AAS community but relevant for users on lipid protocols that include bile acid sequestrants alongside their cycle.
Protocols By Goal
Oral AAS cycle hepatoprotection (17-aa methylated steroids): 500mg/day (harsh orals: 1000mg/day) from day 1 through PCT + 4 weeks.
Pair with NAC 600–1200mg/day. Add dietary fiber 25–35g/day. Monitor ALT/AST at baseline, week 4–6, and 4 weeks post-cycle. Discontinue oral compound if ALT/AST double from baseline.
Oral SARM cycle liver support: 250–500mg/day throughout cycle and 4 weeks PCT. Oral SARMs are less hepatotoxic than 17-aa methylated steroids but still benefit from bile acid support. Escalate to 500mg/day if stacking multiple oral SARMs or running high doses.
General liver maintenance / longevity (no AAS): 250mg/day continuous, taken with breakfast. Appropriate for metabolic health, NAFLD risk mitigation, or hepatoprotection in the context of alcohol, medications, or high-fat diet.
Gut health and bile acid homeostasis: 250mg 2–3× daily before meals (15–30 minutes before eating). Not appropriate for IBS-D.
Insulin sensitivity / metabolic improvement: 750–1750mg/day split into 2–3 doses with meals. The Kars et al. and NCT02218619 trial doses (1750mg/day) likely represent the threshold for significant systemic metabolic benefit; 500mg/day community dosing provides partial metabolic benefit.
Injectable-only AAS cycles: TUDCA not required. 17-alpha methylation is the primary driver of the cholestatic hepatotoxicity TUDCA prevents — injectable esters (Testosterone, Nandrolone, Boldenone) do not undergo this mechanism.
Dosing Details
Standard community dose: 500mg/day split as 250mg twice daily with food. For highly hepatotoxic oral steroids (Superdrol, Anadrol, M1T): escalate to 1000mg/day.
For mild orals (Anavar, Turinabol): 250mg/day may be sufficient. Longevity/metabolic health maintenance: 250–500mg/day. Clinical trial doses: 750mg/day (cirrhosis RCT), 1750mg/day (Kars insulin sensitivity and NCT02218619 T1D beta-cell preservation). Rescue dose (acute hepatotoxicity case): 600mg/day UDCA/TUDCA.
Titration: start at 250mg/day for the first 1–2 weeks, then escalate to target dose. This reduces GI adaptation effects.
Timing: take with food to reduce GI effects. Separate from oral AAS or SARMs by 3–4 hours — bile acid sequestration may reduce oral drug absorption. For GI/bile health applications: before-meal dosing (15–30 minutes prior) may be preferable to stimulate bile flow before fat digestion.
Duration: start on cycle day 1 (not after elevated bloodwork) and continue through PCT — minimum 4 weeks post-cycle. Preventive use is the protocol. For general use: continuous long-term use acceptable at 250mg/day.
Stacks & Alternatives
Complementary mechanisms — TUDCA addresses bile acid homeostasis and CD95/JNK apoptosis; NAC replenishes glutathione and reduces oxidative stress. Together they cover the two primary pathways of oral steroid hepatotoxicity. Monitor GGT: elevated GGT specifically indicates need for more NAC/glutathione; elevated ALT/AST with normal GGT is more TUDCA-responsive. Typical: TUDCA 500mg/day + NAC 600–1200mg/day.
Fiber is functionally required for TUDCA's detoxification mechanism to complete. Without fiber binding bile acids and toxins in the gut, the ~95% enterohepatic re-absorption means most of what TUDCA is trying to excrete gets reabsorbed. Carnivore diet on orals = essentially zero fiber = severe impairment of TUDCA's toxin elimination function. Target 25–35g fiber/day.
Enhances glucuronidation (phase 2 liver detoxification), helping inactivate and excrete steroid metabolites. Synergistic with TUDCA's bile acid excretion mechanism. Cruciferous vegetables provide similar glucuronidation support via DIM/I3C. Typical: 500–1500mg/day.
Provides additional bile acids and bile salts to supplement the bile pool when oral steroids reduce endogenous bile output. Works synergistically with TUDCA, which modulates bile quality and flow rather than just adding volume. Typical: 125–500mg/day with meals.
Alternatives
Stack Cost
TUDCA adds low direct stack tax: it is non-hormonal and easy to dose, but it creates real timing, GI-tolerance, fiber, and liver-lab discipline when used to support hepatotoxic oral cycles.
adverseEffects describes loose stool and increased bowel movement frequency as the most common effect at 500–1000mg/day, with most users adapting within 1–2 weeks and a minority unable to tolerate more than 250mg/day.
stackingConflicts warns that simultaneous dosing with oral AAS/SARMs may alter oral drug absorption or first-pass handling, so the practical rule is a 3–4 hour separation.
TUDCA itself is low-risk, but the oral AAS/SARM contexts it commonly supports require baseline, mid-cycle, and post-cycle liver markers. The monitoring burden belongs to the hepatotoxic stack, not to TUDCA as a standalone supplement.
practicalConsiderations states that 25–35g/day fiber supports the fecal excretion side of the bile-acid/toxin loop; zero-fiber diets weaken the mechanism.
practicalConsiderations flags a common label issue where a serving is 500mg but each capsule is 250mg, creating unintentional half-dosing if the user does not check the per-capsule amount.
- ·Treat TUDCA as support for the oral-hepatotoxic lane, not as permission to stack multiple 17-alpha-alkylated orals.
- ·Separate TUDCA from oral AAS/SARMs by 3–4 hours and avoid taking it with bile-acid sequestrants.
- ·Start at 250mg/day for 1–2 weeks if GI tolerance is uncertain, then increase to the protocol dose.
- ·For oral AAS/SARM support, obtain baseline liver markers and repeat mid-cycle and post-cycle; stop the offending oral if ALT/AST double from baseline or bilirubin rises materially.
- ·Keep fiber intake in the 25–35g/day range unless medically contraindicated.
- ·CMP liver markers, bilirubin, ALP, and GGT when the user is running oral AAS/SARMs or has existing liver-risk context.
- ·NAC/glutathione support when GGT suggests oxidative stress demand rather than isolated cholestatic/bile-acid stress.
- ·Dietary fiber and basic GI tolerance management.
Practical Setup
Purchasing: OTC supplement in the US. Pharmaceutical-grade preferred for dosing consistency. Reputable brands include Nutricost and Double Wood Supplements.
Critical label caveat: many brands list '500mg per serving' requiring 2 capsules — a single capsule may only be 250mg. Verify per-capsule dose before assuming standard dosing. This is a documented cause of unintentional 50% underdosing in new users.
Fiber is not optional: dietary fiber (25–35g/day) is functionally required for TUDCA to complete its detoxification mechanism. Without fiber binding bile acids and toxins in the gut, the ~95% enterohepatic re-absorption loop means most toxins recirculate. A carnivore diet with zero fiber dramatically reduces TUDCA's effectiveness and is specifically highlighted as the reason for elevated bilirubin in carnivore dieters on oral steroids.
GGT monitoring: use GGT to distinguish which support supplement is most needed. GGT elevated = oxidative stress pathway demand = prioritize NAC/glutathione. ALT/AST elevated with normal GGT = cholestatic/bile acid stress = prioritize TUDCA. Running both covers all pathways.
Injectable-only cycles: TUDCA not required. 17-alpha methylation is the specific mechanism TUDCA protects against — injectable AAS (Testosterone, Nandrolone, Boldenone, etc.) do not carry this mechanism.
Insulin sensitivity context: clinical doses for metabolic benefit (Kars, NCT02218619) are 1750mg/day — above the community standard 500mg/day. If metabolic health improvement is a primary goal, consider escalating dose with GI tolerance assessment.
IBS-D warning: bile acids are prokinetic by mechanism. IBS-D (diarrhea-predominant) users should start at 125–250mg/day and carefully assess GI response before escalating.
Mechanism Deep Dive
TUDCA operates via two parallel, synergistic protective mechanisms.
1. Bile acid homeostasis and anti-apoptotic signaling: TUDCA stimulates bile flow by activating α5β1 integrin in hepatocytes — transferring the β1 subunit to its active conformation, which drives insertion of BSEP (bile salt export pump) and NTCP (Na+/taurocholate co-transporting polypeptide) into the hepatocyte canalicular and sinusoidal membranes. This increases bile acid export and re-uptake, normalizing the bile acid cycle disrupted by oral steroids. Separately, TUDCA blocks toxic hydrophobic bile acid-induced apoptosis (the kind triggered when BSEP fails and toxic bile acids accumulate in hepatocytes): it generates cAMP → PKA activation → MKP-1 (MAPK phosphatase 1) → JNK dephosphorylation → CD95 death receptor blockade. The CD95/EGFR association that initiates the apoptotic cascade is inhibited.
2. Chemical chaperone / ER stress reduction: the endoplasmic reticulum (ER) folds secretory and membrane proteins. When unfolded proteins accumulate (ER stress), the unfolded protein response (UPR) activates three branches: ATF6 (adaptive), IRE1 (adaptive/compensatory), and PERK-eIF2α-CHOP (pro-death if chronic). TUDCA activates the protective ATF6 arm (improving folding capacity) and activates PERK → eIF2α → ATF4 signaling selectively WITHOUT inducing CHOP (the transcription factor that drives apoptosis) or BiP upregulation. This selective UPR modulation tips the balance toward cellular adaptation and survival rather than death — explaining why TUDCA outperforms PBA (which lacks this selectivity) in vitro.
3. Enterohepatic recycling and functional duration: TUDCA's plasma half-life is 1–2 hours but functional duration is 8–12 hours due to enterohepatic recycling. Bile acids absorbed intestinally undergo extensive hepatic first-pass extraction and are re-secreted into bile, cycling 2–3 times before eventual fecal excretion. This recycling extends protection beyond what the short plasma half-life suggests. It also means dietary fiber is mechanistically required — fiber binds bile acids and toxins in the gut, diverting them to fecal excretion instead of recirculation. Without fiber, TUDCA's detoxification loop is incomplete.
4. Downstream gut-liver axis effects: oral steroid-induced bile viscosity disruption creates a cascade — impaired bile flow → reduced intestinal pH buffering → altered gut microbiome (bile acid composition is a primary microbiome determinant) → disrupted serotonin production (95% gut-derived) → mood effects, appetite suppression → impaired leptin signaling → nausea and reduced appetite at high oral doses. TUDCA addresses the root cause of this cascade by restoring bile acid homeostasis.
Evidence Index
Quantitative claims trace to these source studies. Population, dose, and study type matter — claims from HIV-lipodystrophy trials don't transfer cleanly to healthy adults; data from supraphysiologic doses doesn't apply at TRT.
A multicenter PBC RCT found TUDCA 750mg/day non-inferior to UDCA for ALP reduction and liver-function normalization over 24 weeks, with better tolerability described in the article.
Supports bile-acid therapy and tolerability in cholestatic disease; it does not directly prove preventive efficacy during oral steroid cycles.
A liver-cirrhosis RCT reported significant ALT, AST, and bilirubin reduction at 750mg/day versus placebo.
Small disease-population trial; useful for liver-enzyme directionality, not a standalone dosing proof for healthy users.
A real-world AAS support-stack report described AST falling from 70 to 48 units/L and ALT from 65 to 39 units/L, roughly 30–40% improvement, while using TUDCA + NAC + injectable glutathione + carnitine.
Highly relevant context but confounded by multiple support compounds and cycle-dose changes.
An acute hepatotoxicity case after 1000mg/week trenbolone reported bilirubin 11x upper limit, ALT 7.5x ULN, and AST 4.5x ULN at admission, then return to baseline within 1 month after UDCA/TUDCA 600mg/day post-hospitalization.
Rescue context after medical care; should not be generalized as proof that TUDCA can neutralize reckless dosing.
Kars et al. reported improved systemic and hepatic insulin sensitivity at 1750mg/day.
This is the key dose boundary for metabolic claims; common 250–500mg/day supplement dosing should not inherit the full expected effect.
Forum reports in the article estimate that most users adapt to loose stool within 1–2 weeks, while a minority around 10–15% cannot tolerate more than 250mg/day.
Useful practical tolerance signal, not a controlled adverse-event rate.
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.